A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)

• Status: Completed
• Trial end date: 2010-06-01
• Target enrollment: 0
• Participant gender: All

Summary

30-40% of patients with lung cancer will develop bone metastases during the course of their disease, which can lead to pain, decreased mobility and skeletal complications. This study will investigate the effect of zoledronic acid on preventing or delaying the development of bone metastases and the impact on disease progression/survival in patients with stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC).

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Novartis Pharmaceuticals
• Treatments: Diphosphonates; Zoledronic Acid

Criteria

Inclusion Criteria:

• Histologically or cytologically confirmed Non-small Cell Lung Cancer (NSCLC)

• Newly Diagnosed, Stage IIIA and Stage IIIB excluding patients with pleural effusion

• Patients must have received primary treatment for their disease and had no progression

Exclusion Criteria:

• Diagnosed with NSCLC longer than 6 months ago

• Treatment with other bisphosphonates in past 12 months

• Presence of metastases

Other protocol-defined inclusion and exclusion criteria may apply.